| pubmed-article:17692343 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17692343 | lifeskim:mentions | umls-concept:C0025260 | lld:lifeskim |
| pubmed-article:17692343 | lifeskim:mentions | umls-concept:C0019564 | lld:lifeskim |
| pubmed-article:17692343 | lifeskim:mentions | umls-concept:C0001041 | lld:lifeskim |
| pubmed-article:17692343 | lifeskim:mentions | umls-concept:C2936516 | lld:lifeskim |
| pubmed-article:17692343 | lifeskim:mentions | umls-concept:C0679622 | lld:lifeskim |
| pubmed-article:17692343 | lifeskim:mentions | umls-concept:C2349975 | lld:lifeskim |
| pubmed-article:17692343 | lifeskim:mentions | umls-concept:C0205314 | lld:lifeskim |
| pubmed-article:17692343 | lifeskim:mentions | umls-concept:C2001140 | lld:lifeskim |
| pubmed-article:17692343 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:17692343 | pubmed:dateCreated | 2007-8-27 | lld:pubmed |
| pubmed-article:17692343 | pubmed:abstractText | Recent evidence suggests that 5-hydroxytryptamine (5-HT)(4) receptor activity enhances cognition and provides neuroprotection. Here we report the effects of VRX-03011, a novel partial 5-HT(4) agonist, that is both potent (K(i) approximately 30 nM) and highly selective (K(i) > 5 microM for all other 5-HT receptors tested). In separate experiments, rats received VRX-03011 (0.1-10 mg/kg i.p.) 30 min prior to spontaneous alternation testing in a no-delay or a 30-s delay condition. VRX-03011 (1, 5 and 10 mg/kg, but not 0.1 mg/kg) significantly enhanced delayed spontaneous alternation performance while none of the doses enhanced performance in the no-delay test. VRX-03011 (1 and 5 mg/kg) concomitantly enhanced hippocampal acetylcholine output and delayed spontaneous alternation scores compared to that of vehicle controls, but had no effect on hippocampal acetylcholine release under a resting condition. Moreover, suboptimal doses of VRX-03011 and the acetylcholinesterase inhibitor galanthamine combined to enhance memory. VRX-03011 also regulated amyloid precursor protein (APP) metabolism by inducing a concentration-dependent increase in the non-amyloidogenic soluble form of APP (sAPPalpha) with an EC(50) approximately 1--10 nM. VRX-03011 had no effect on contractile properties in guinea pig ileum or colon preparations with an EC(50) > 10 microM and did not alter rat intestinal transit at doses up to 10 mg/kg. These findings suggest that VRX-03011 may represent a novel treatment for Alzheimer's disease that reduces cognitive impairments and provides neuroprotection without gastrointestinal side effects. | lld:pubmed |
| pubmed-article:17692343 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17692343 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17692343 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17692343 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17692343 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17692343 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17692343 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17692343 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17692343 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17692343 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17692343 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:17692343 | pubmed:issn | 0028-3908 | lld:pubmed |
| pubmed-article:17692343 | pubmed:author | pubmed-author:BockaertJoelJ | lld:pubmed |
| pubmed-article:17692343 | pubmed:author | pubmed-author:DumuisAlineA | lld:pubmed |
| pubmed-article:17692343 | pubmed:author | pubmed-author:RagozzinoMich... | lld:pubmed |
| pubmed-article:17692343 | pubmed:author | pubmed-author:GoldPaul EPE | lld:pubmed |
| pubmed-article:17692343 | pubmed:author | pubmed-author:Lezoualc'hFra... | lld:pubmed |
| pubmed-article:17692343 | pubmed:author | pubmed-author:GastineauMoni... | lld:pubmed |
| pubmed-article:17692343 | pubmed:author | pubmed-author:ShachamSharon... | lld:pubmed |
| pubmed-article:17692343 | pubmed:author | pubmed-author:MarantzYaelY | lld:pubmed |
| pubmed-article:17692343 | pubmed:author | pubmed-author:NoimanSilviaS | lld:pubmed |
| pubmed-article:17692343 | pubmed:author | pubmed-author:RobertSylvain... | lld:pubmed |
| pubmed-article:17692343 | pubmed:author | pubmed-author:MohlerEric... | lld:pubmed |
| pubmed-article:17692343 | pubmed:author | pubmed-author:RutkowskiJose... | lld:pubmed |
| pubmed-article:17692343 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17692343 | pubmed:volume | 53 | lld:pubmed |
| pubmed-article:17692343 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17692343 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17692343 | pubmed:pagination | 563-73 | lld:pubmed |
| pubmed-article:17692343 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:17692343 | pubmed:meshHeading | pubmed-meshheading:17692343... | lld:pubmed |
| pubmed-article:17692343 | pubmed:meshHeading | pubmed-meshheading:17692343... | lld:pubmed |
| pubmed-article:17692343 | pubmed:meshHeading | pubmed-meshheading:17692343... | lld:pubmed |
| pubmed-article:17692343 | pubmed:meshHeading | pubmed-meshheading:17692343... | lld:pubmed |
| pubmed-article:17692343 | pubmed:meshHeading | pubmed-meshheading:17692343... | lld:pubmed |
| pubmed-article:17692343 | pubmed:meshHeading | pubmed-meshheading:17692343... | lld:pubmed |
| pubmed-article:17692343 | pubmed:meshHeading | pubmed-meshheading:17692343... | lld:pubmed |
| pubmed-article:17692343 | pubmed:meshHeading | pubmed-meshheading:17692343... | lld:pubmed |
| pubmed-article:17692343 | pubmed:meshHeading | pubmed-meshheading:17692343... | lld:pubmed |
| pubmed-article:17692343 | pubmed:meshHeading | pubmed-meshheading:17692343... | lld:pubmed |
| pubmed-article:17692343 | pubmed:meshHeading | pubmed-meshheading:17692343... | lld:pubmed |
| pubmed-article:17692343 | pubmed:meshHeading | pubmed-meshheading:17692343... | lld:pubmed |
| pubmed-article:17692343 | pubmed:meshHeading | pubmed-meshheading:17692343... | lld:pubmed |
| pubmed-article:17692343 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17692343 | pubmed:articleTitle | VRX-03011, a novel 5-HT4 agonist, enhances memory and hippocampal acetylcholine efflux. | lld:pubmed |
| pubmed-article:17692343 | pubmed:affiliation | Department of Psychology, University of Illinois at Chicago, Chicago, IL 60607, USA. | lld:pubmed |
| pubmed-article:17692343 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17692343 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
